NLS Pharmaceutics (NLSP)

• Market cap: $3.85M
• 1 day: -29.52%
• 5 days: -47.89%
• 1 month: -69.8%
• 3 months: -61.86%
• 6 months: -51.63%
• Year to date: -66.06%
• 1 year: -82.08%
• 5 years: -99.36%
• 10 years: -99.36%
• Sector: Healthcare
• Industry: Biotechnology

About: NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

Employees: 1